Last edition
News about "Zydus Lifesciences"
Zydus Lifesciences reported a robust performance for the second quarter ended September 30, 2025, with net profit rising over 38 percent to INR 1,258.6 crore, compared to INR 911.2 crore in the same quarter last year.
Zydus Lifesciences | 06/11/2025 | By Darshana
Zydus Receives USFDA Approval for Deflazacort Oral Suspension
Zydus stated that deflazacort oral suspension will be produced at Doppel, Italy.
Zydus Lifesciences | 06/10/2025 | By Dineshwori
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
Zydus Lifesciences | 04/10/2025 | By Dineshwori | 106
ICMR Licenses Nine Health Tech Innovations at India MedTech Expo 2025
At the India MedTech Expo 2025 in Delhi, ICMR licensed nine breakthrough technologies to industry partners under its Patent Mitra initiative, sealing 17 deals in diagnostics and vaccine development to advance affordable, homegrown healthcare.
Zydus Lifesciences | 05/09/2025 | By Dineshwori | 107
Zydus and Synthon Sign Exclusive Licensing and Supply Agreement for Ozanimod Capsules for US Market
Zydus Lifesciences’ subsidiary Zydus Lifesciences Global FZE has signed an exclusive licensing and supply deal with Synthon BV to commercialise generic Ozanimod Capsules (ZEPOSIA) in the US market.
Zydus Lifesciences | 05/09/2025 | By Mrinmoy Dey
Zydus Wellness Buys UK-Based Comfort Click for INR 2,800 Crore to Enter Global VMS Market
Zydus Wellness, the consumer care arm of Zydus Lifesciences, has announced its first international acquisition with the buyout of UK-based vitamins and supplements company Comfort Click for approximately INR 2,800 crore (GBP 239 million).
Zydus Lifesciences | 30/08/2025 | By Darshana | 163
Zydus Reports Positive Phase 3 Results for Saroglitazar in Primary Biliary Cholangitis
The study met its primary endpoint, showing a 48.5% treatment difference in biochemical response with Saroglitazar 1 mg compared to placebo (P<0.001). Biochemical response was defined by improvement in alkaline phosphatase (ALP) and bilirubin, key markers of PBC progression.
Zydus Lifesciences | 29/08/2025 | By Darshana
Zydus Secures Final USFDA Approval for Diltiazem Hydrochloride Tablets
Zydus Lifesciences has received final USFDA approval to market Diltiazem Hydrochloride Tablets in 30 mg, 60 mg, 90 mg, and 120 mg dosages for the treatment of chronic stable angina and angina due to coronary artery spasm in the US.
Zydus Lifesciences | 11/08/2025 | By Mrinmoy Dey | 134
Zydus Acquires 85.6 Percent Stake in Amplitude Surgical for EUR 256 Million
Zydus Lifesciences Ltd. has completed the EUR 256 million acquisition of an 85.6 percent stake in France-based Amplitude Surgical, marking a strategic move to strengthen its global presence in the orthopaedics space.
Zydus Lifesciences | 30/07/2025 | By Mrinmoy Dey | 136
Zydus Secures Final Approval from USFDA for Niacin Extended-Release Tablets
Zydus Lifesciences has received final USFDA approval to manufacture Niacin Extended-Release Tablets in 500 mg, 750 mg, and 1,000 mg dosage, targeting cholesterol management and cardiovascular risk reduction.
Zydus Lifesciences | 30/04/2025 | By Abha | 348
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy